Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-grade serous ovarian, fallopian tube, or primary peritoneal cancer that has come back or gotten worse after at least one prior treatment.
- Your tumor has been tested for a specific gene change called KRAS.
- You are able to try one of the standard treatments: pegylated liposomal doxorubicin, paclitaxel, letrozole, or anastrozole.
- Your cancer can be measured on a scan (CT or MRI).
- You are up and about (able to do light work or daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
This trial lets people who are already doing well on a study treatment keep receiving it. It tests whether continuing the combination of avutometinib and defactinib remains safe and helpful for recurrent low-grade serous ovarian cancer.
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of three targeted drugs (avutometinib, defactinib, and everolimus) for people whose endometrial cancer has a specific change in the RAS pathway and has not responded to other treatments. The goal is to see if this drug combo can shrink tumors or slow their growth.
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
Hear when a new Low Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.